Coherent Market Insights

Organ Preservation Solutions Market to Reach US$ 695.0 Million by 2027

Organ Preservation Solutions Market to Reach US$ 695.0 Million by 2027 - Coherent Market Insights

Publish In: Sep 03, 2020

Organ preservation involves removal of organs from the bodies, which are then stored for transplantation. Organ preservation systems are exclusively prepared and maintained according to the biological environment (temperature and oxygen) needed to store particular organs.

The global organ preservation solutions market is estimated to account for US$ 238.7 Mn in terms of value in 2020 and is expected to reach US$ 695.0 Mn by the end of 2027.

Global Organ Preservation Solutions Market: Drivers

R&D in organ transplant is expected to propel growth of the global organ preservation solutions market over the forecast period. For instance, in August 2020, researchers at the Friedrich-Alexander-University Erlangen-Nürnberg, Germany, reported that the rejection of a kidney transplant was found to be the cause of intestinal bleeding and pain in a woman with atypical hemolytic uremic syndrome without systemic symptoms.

Global Organ Preservation Solutions Market: Opportunities

Implementation of favorable reimbursement scenario is expected to offer lucrative growth opportunities for players in the global organ preservation market. For instance, in January 2020, The Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2019 (HR 5534) extended Medicare coverage of immunosuppressive drugs for kidney transplants past the 36-month cut-off currently in place to cover the medications for the life of the transplant.

Global Organ Preservation Solutions Market: Restraints

Lack of donor organs is expected to hinder growth of the global organ preservation solutions market. Despite advances in medicine and technology and increased awareness about organ donation and transplantation, the gap between demand and supply continues to widen.

Key Takeaways:

The global organ preservation solutions market was valued at US$ 204.9 Mn in 2019 and is forecast to reach a value of US$ 695.0 Mn by 2027 at a CAGR of 16.5% between 2020 and 2027. Major factor driving the growth of global organ preservation solutions market during the forecast period include increasing prevalence of diseases, and increasing demand for organ transplants.

Custodiol HTK held dominant position in the global organ preservation solutions market in 2019, accounting for 51.1% share in terms of value, followed by Viaspan and Perfadex, respectively.

Market Trends

Emergence of Covid-19 pandemic has adversely impacted the rate of organ transplant. For instance, the study, ‘Pandemic‐related unemployment impacts transplant in the US’, published in July 2020, reported that the COVID‐19 pandemic increased unemployment in the U.S., thereby leaving many people without health insurance. Lack of insurance and income may mean that patients cannot progress through the pre-transplant visits or pay for critical immunosuppressive medication post-transplant.

R&D in organ preservation is expected to propel growth of the global organ preservation solutions market over the forecast period. For instance, in July 2019, researchers from UT Health San Antonio reported development of a novel organ transplant device that preserves organs, limbs for at least 24 hours.

Global Organ Preservation Solutions Market: Competitive Landscape   

Major players operating in the global organ preservation market include, Teva Pharmaceutical Industries Ltd., Dr. Franz Köhler Chemie GmbH, BioLife Solutions, XVIVO Perfusion AB, Bristol-Myers Squibb, Inc., and ToleroTech, Inc., Lifeline Scientific, Preservation Solutions Inc., Claris Injectables Limited, 21st Century Medicine, Paragonix Technologies Inc., BioTime, Inc. CryoLife, Inc., and Dr. Franz Köhler Chemie GmbH.

Global Organ Preservation Solutions Market: Key Developments

Major players in the market are focused on approval and launch of new devices to expand their product portfolio. For instance, in February 2020, Paragonix Technologies Inc. received the US Food and Drug Administration (FDA) 510(k) clearance for its Paragonix SherpaPak Pancreas Transport System.

Segmentation

  • By Solution Type
    • Viaspan
    • Custodiol HTK
    • Renograf
    • Hypothermosol
    • Perfadex
    • Lifor
    • HBS Solution
    • siRNA
    • Others
  • By Technique Type
    • Hypothermic Perfusion Preservation
    • Static Cold Storage
    • Others
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail


Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.